A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors
Latest Information Update: 06 Aug 2024
At a glance
- Drugs Cisplatin (Primary) ; Fluorouracil (Primary) ; Lenvatinib (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Vibostolimab+pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Liver cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms KEYVIBE-005
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 01 Aug 2024 Planned End Date changed from 22 Feb 2027 to 12 Aug 2026.
- 01 Aug 2024 Planned primary completion date changed from 22 Feb 2027 to 12 Aug 2026.
- 01 Aug 2024 Status changed from recruiting to active, no longer recruiting.